Cite
HARVARD Citation
Patel, K. et al. (2020). Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 61 (14), pp. 3387-3394. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Patel, K. et al. (2020). Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 61 (14), pp. 3387-3394. [Online].